key: cord-0914375-u1fmf4pg authors: Alberici, Federico; Delbarba, Elisa; Manenti, Chiara; Econimo, Laura; Valerio, Francesca; Pola, Alessandra; Maffei, Camilla; Possenti, Stefano; Zambetti, Nicole; Moscato, Marianna; Venturini, Margherita; Affatato, Stefania; Gaggiotti, Mario; Bossini, Nicola; Scolari, Francesco title: A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. date: 2020-04-09 journal: Kidney Int DOI: 10.1016/j.kint.2020.04.002 sha: 6d4c6b9d8663d1865ebc23f4b2b8d86a1ec3f160 doc_id: 914375 cord_uid: u1fmf4pg The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality. The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15] [16] [17] [18] [19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality. Keywords: transplantation, acute kidney injury, inflammation, tocilizumab SARS-CoV-2 infection is posing challenges to all the health systems in the world. The ideal therapeutic approach is still debated and data on subgroups of patients at high risk still scarce(1). We have developed an internal treatment protocol for the management of renal transplant patients with SARS-CoV-2 pneumonia (2). Since the first days of March 2020 we reorganised our ward to admit kidney transplant patients with SARS-CoV2 pneumonia; we felt this rearrangement as necessary since our centre acts as referral for a population of 1200 kidney transplant patients. Due to the onset of the COVID-19 epidemic, acute transplantation surgery was suspended in our centre from the 20th of February 2020. The first admission of a transplant patient with SARS-CoV2 pneumonia occurred on the 27th of February 2020, the second one six days later and subsequently up to the 24thof March 2020 (day of when this analyses was performed and patients follow-up censored) an average rate of 1.2 kidney transplant patients were admitted per day . We describe here the clinical course and renal outcomes of the first 20 kidney transplant recipients admitted and followed in our unit with pneumonia secondary to SARS-CoV-2 infection. In this report we describe the progress of all kidney transplant patients with SARS-CoV2 pneumonia admitted up to the 24th of March 2020. These patients had a median inpatient stay of 7 days (IQR 4-15) and the main baseline clinical characteristics are shown in Table 1 and Table 2 . Briefly, all patients presented with fever, however only 1/20 complained of dyspnoea; 50% of the transplant patients had radiographic changes of bilateral infiltrates on admission, while the remaining 50% showed unilateral changes or no infiltrates; 7/20 did not require supplemental oxygen. All patients had their usual transplant immunosuppression withdrawn and were started on methylprednisolone 16 mg or equivalent dose of prednisone, 19/20 received antiviral therapy and hydroxychloroquine as per our protocol (2) . As anti-viral therapy is known to interfere with calcineurin inhibitor metabolism, in four patients tacrolimus levels were monitored after these therapeutic changes were instituted. The median trough values before anti-viral therapy were 7.05 ng/ml(IQR 5.5-8.6); one patient had the level re-checked after 3 days with no change compared to baseline, one patient had the level rechecked 4 and 5 days after admission (-17% and -18% compared to baseline), one six days after admission (-12% compared to baseline) and one 8 days after admission (-21% compared to baseline). The median times from symptom onset and admission to these therapeutic changes were respectively 5 days (IQR 3-8.25) for antiviral therapy and 0 days (IQR 0-0) for hydroxychloroquine . During the follow-up one patient had hydroxychloroquine withdrawn due to toxicity (nausea, vomiting) but no prolongation of the cardiac QTc interval compared to baseline or cardiac arrhythmias were observed. Antibiotics were administered to 11/20 kidney transplant recipients (55%): cephalosporins in 64%, beta-lactams in 36%, fluoroquinolones in 25%, carbapenems in 10% and glycopeptides in 5%. During hospitalization chest radiographs were repeated in 15/20 patients and radiological findings worsened in 13/15 (87%). The changes of the main blood tests compared to baseline are shown in Supplementary Figure S1 . In the individuals with worsening radiological findings, 11/13 (85%) required an escalation of the oxygen supplemental therapy; comprising: one patient switched from regular breathing to low oxygen requirement (LOR), 3/15 from regular breathing to high oxygen requirement (HOR), 2/15 from HOR to non-invasive ventilation (NIV) and 2/15 from HOR to mechanical ventilation (MV). Additional anti-inflammatory therapy comprising dexamethasone and tocilizumab were given to 11/20 (55%) and 6/20 (30%) patients, (see supplementary material for protocol details); in these patients, 4/11 (36%) and 2/6 (33%) subsequently died. The characteristics of the patients treated with tocilizumab are shown in Table 3 ; among these patients, 3/6 (50%) experienced a reduction of the oxygen requirements and 2/6 (33%) showed amelioration of the radiological findings. Two out of the six patients who were treated with tocilizumab eventually died and one was discharged from hospital 9 days after the administration of tocilizumab. In terms of kidney function, the medium creatinine level at admission was +17% (IQR 12-26%, range 0 -143%) compared to baseline and the highest creatinine level observed during the follow-up was +33% (IQR 13-59%, range 0 -157%) compared to baseline; 6/20 patients developed AKI and 1/6 required haemodialysis. Three patients were discharged, after 7 days in one case and after 16 in the 2 remaining cases; at discharge creatinine level compared to baseline was 3.6 vs 2.1, 2.3 vs 2.5 and 2.1 vs 1.5 mg/dl. In terms of immunosuppressive therapy, two patients were discharged receiving methylprednisolone 16 mg and one with methylprednisolone 12 mg per day. SARS-CoV2 infection is challenging health care systems around the world. The mortality of the disease has been proposed to be around the 2.3% with age and comorbidities such as cardiovascular diseases, diabetes, chronic respiratory diseases, hypertension and cancer being associated with worse prognoses (4, 5) . Immunosuppression and CKD may represent The role of lopinavir/ritonavir in SARS-CoV2 management is debated, with some data supporting a greater benefit with early start compared to a delayed commencement (1); our cohort was started on antiviral therapy a median of 5.5 days after symptom onset. Lopinavir/ritonavir may interact with CNIs impacting on their level: the four patients of our cohort with serial CNI monitoring confirmed that; of note none of these patients died and 3/4 have been discharged. Reports suggest a role for hydroxychloroquine treatment in reducing the viral load(6). In our cohort, 19/20 patients received this drug although toxicity led to treatment withdrawal in one case. Hydroxychloroquine and lopinavir/ritonavir may interact causing a prolongation of the cardiac QTc, interval however none of this series experienced this complication. Preliminary data and understanding of the pathogenesis of the pneumonia secondary to SARS-CoV-2 infection suggest a central role of inflammatory cytokines in inducing the rapid clinical deterioration in association with worsening chest radiology and escalating oxygen requirement , observed in an average of 7-10 days from the symptom onset (7) . In this context glucocorticoids and tocilizumab have been suggested to be a therapeutic strategy (8) . Our subgroup of patients treated by this approach experienced a poor outcome, although encouraging signals in terms of potential beneficial effects were observed in the patients treated with tocilizumab: 50% reduced oxygen therapy requirement and 33% experiencing improvement of radiological changes. Despite that, two patients died. Our results are too preliminary and the sample size too small to draw firm conclusions. The high mortality rate of this population suggests aggressive management is needed for kidney transplant patients with SARS-CoV2 infection, in particular early hospitalization should be considered in case of pneumonia; furthermore more effective treatment protocols need to be identified. Our study has limitations: the sample size is small and the median follow-up short; findings are, therefore, preliminary and will need to be confirmed in bigger cohorts with longer followup. Some strengths may be acknowledged as well and in particular the monocentric approach and the homogeneity of the clinical treatment employed. In conclusion, kidney transplant patients with SARS-CoV2 pneumonia may present with an unfavourable disease course and a poor outcome; hospitalization is required and repeat chest x-ray advisable. Clinical management needs to be improved in order to impact on these patients' prognosis. According to the Italian regulations, ethical approval for the study has been obtained. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Mangement of patients on dialysis and with kidney transplant during COVID-19 coronavirus infection KDIGO clinical practice guidelines for acute kidney injury The Novel Coronavirus Pneumoniae emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Disease (COVID-19) -China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Figure S1 : Changes of WBC, LDH, AST, ALT, CRP and creatinine compared to baseline.